Tango Therapeutics(US:TNGX)2025-10-23 13:32Summary of Tango Therapeutics Conference Call on VOCA Medi-Stat Clinical Data Company Overview - Company: Tango Therapeutics (NasdaqGM:TNGX) - Focus: Development of cancer drugs targeting genes frequently deleted in human cancers, specifically through the concept of synthetic lethality [3][22] Key Points on VOCA Medi-Stat - Drug Name: VOCA Medi-Stat (formerly TNG462) - Mechanism: PRNP-5 inhibitor designed for cancers with MTAP deletion, sparing normal cells [3][4] - Target Population: Approximately 60,000 patients annually in the U.S. with MTAP-deleted solid tumors, including pancreatic and lung cancers [5][6] Clinical Development - Initial Focus: Pancreatic cancer, with 20,000 MTAP-deleted cases annually in the U.S. [4] - Pivotal Study Plans: First pivotal study planned for 2026 in second-line MTAP-deleted pancreatic cancer [4][22] - Combination Trials: Ongoing trials combining VOCA Medi-Stat with RAS inhibitors (daraxonrasib and zoldonrasib) to explore chemotherapy-free treatment options [4][17] Clinical Data Highlights - Overall Response Rate: 27% across all patients, with a median progression-free survival (PFS) of 6.4 months [9][11] - Second-Line Pancreatic Cancer: Median PFS of 7.2 months and overall response rate of 25%, significantly better than historical standards of care [9][15] - Histology-Agnostic Cohort: Overall response rate of 49% with a median PFS of 9.1 months, indicating strong activity across multiple cancer types [19][20] Safety and Tolerability - Safety Profile: Best-in-class safety profile with no drug-related discontinuations and a low dose reduction rate of 8% [9][12] - Adverse Events: Most adverse events were grade 1, with no grade 4 or 5 events reported [12][21] - Dosing Strategy: Optimized dosing at 250 mg daily, balancing efficacy and tolerability [12][60] Future Outlook - Upcoming Data Releases: Strong cadence of disclosures planned for 2026, including updates on combination studies and initial data from first-line pancreatic cancer cohorts [8][20] - Market Positioning: VOCA Medi-Stat positioned to be the first MTAP-selective PRNP-5 inhibitor to market, with significant potential in multiple cancer types [20][22] Additional Considerations - Regulatory Interactions: Plans for FDA interactions regarding pivotal study design and control regimens [27][45] - Screening Rates: Estimated MTAP deletion screening rate in the U.S. is about 40%, with ongoing efforts to improve this for better patient enrollment [52][56] - Companion Diagnostics: Development of companion diagnostics for rapid MTAP deletion screening to facilitate patient enrollment [56] This summary encapsulates the critical insights from the conference call regarding Tango Therapeutics' VOCA Medi-Stat, highlighting its clinical development, safety profile, and future plans in the oncology landscape.